Apixaban is an anticoagulant medication used to treat and prevent blood clots and to prevent strokes in people with atrial fibrillation. In particular, it is used to prevent blood clots after hip or knee replacement surgery and in people who have been previously diagnosed with blood clots. It is preferred as an alternative to warfarin, it does not require monitoring by blood tests, can be taken orally, and has a more favorable side effect profile. It is taken by mouth.
In 2007, Pfizer and Bristol-Myers Squibb began developing apixaban as an anticoagulant. Apixaban was approved for medical use in the European Union in May 2011 and in the United States in December 2012. It is on the World Health Organization's list of essential medicines.